Teva Pharmaceutical Industries (TEVA) Long-Term Debt Repayments (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Long-Term Debt Repayments for 18 consecutive years, with $23.0 million the latest figure, recorded in Q1 2026.

• Quarterly Long-Term Debt Repayments changed N/A year-over-year to $23.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 68.62% YoY) and the FY2025 annual result came in at $4.1 billion, up 150.58% from the prior year.
• Long-Term Debt Repayments slipped to $23.0 million in Q1 2026 per TEVA's latest filing, from $444.0 million in the prior quarter.
• Over the last five years, Long-Term Debt Repayments for TEVA reached as high as $3.2 billion in Q1 2023 and fell as low as $23.0 million in Q1 2026.
• A 5-year average of $992.9 million and a median of $696.5 million in 2022 frame the typical range for Long-Term Debt Repayments.
• Annual changes were most pronounced in 2022 — Long-Term Debt Repayments slumped 86.32% — and 2023, when it soared 173.97%.
• Year by year, Long-Term Debt Repayments stood at $708.0 million in 2022, then soared by 41.24% to $1.0 billion in 2023, then sank by 31.5% to $685.0 million in 2024, then slumped by 35.18% to $444.0 million in 2025, then slumped by 94.82% to $23.0 million in 2026.
• According to Business Quant data, Long-Term Debt Repayments over the past three periods registered $23.0 million, $444.0 million, and $2.3 billion for Q1 2026, Q3 2025, and Q2 2025 respectively.